http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Ha-young Choi ),( Hyeok-gyu Lee ),( A-ra Cho ),( Sang-ho Park ),( Seung-woon Rha2 ) 대한내과학회 2016 대한내과학회 추계학술발표논문집 Vol.2016 No.1
Introduction: Obesity, metabolic syndrome and diabetes mellitus are risk factor of coronary artery disease (CAD). Fibroblast growth factor 21 (FGF21) is secreted primarily from liver that exerts potent anti-diabetic and lipid lowering effects in animal models of obesity and type 2 diabetes mellitus. In recent studies showed FGF21 has similar effects in human subjects and also related with obesity and metabolic syndrome. However, the relationship between serum FGF21 level and CAD is not yet unknown. Objective: This study aimed to investigate the relationship among serum FGF21 levels, various cardiometabolic parameters and CAD in type 2 diabetic patients. Methods: In a total of 168 Korean adults with diabetes mellitus, in whom coronary angiogram were performed and classified into CAD group (n=99) and non-CAD group (n=69). Significant coronary artery stenosis was defiened as a coronary angiography finding of more than 50% stenosis in 1 ≥ coronary arteries. Fasting serum FGF21 level were measured using ELISA. Results: Serum mean FGF21 level in type 2 diabetes mellitus with CAD showed lower than in type 2 diabetes mellitus without CAD (1.10±0.22 pg/mL vs. 1.27±0.16 pg/mL, p<0.05). Conclusions: The Result suggest that fasting serum FGF21 levels might be a predictive marker of coronary artery diseases in Korean patients with type 2 diabetes mellitus
Rha, Seung-Woon,Choi, Byoung Geol,Baek, Man Jong,Ryu, Yang gi,Li, Hu,Choi, Se Yeon,Byun, Jae Kyeong,Mashaly, Ahmed,Park, Yoonjee,Jang, Won Young,Kim, Woohyeun,Choi, Jah Yeon,Park, Eun Jin,Na, Jin Oh,C Yonsei University, College of Medicine 2018 Yonsei medical journal Vol.59 No.5
<P><B>Purpose</B></P><P>Many recent studies have reported that successful percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) for chronic total occlusion (CTO) has more beneficial effects than failed CTO-PCI; however, there are only limited data available from comparisons of successful CTO-PCI with medical therapy (MT) in the Korean population.</P><P><B>Materials and Methods</B></P><P>A total of 840 consecutive CTO patients who underwent diagnostic coronary angiography, receiving either PCI with DESs or MT, were enrolled. Patients were divided into two groups according to the treatment assigned. To adjust for potential confounders, propensity score matching (PSM) analysis was performed using logistic regression. Individual major clinical outcomes and major adverse cardiac events, a composite of total death, myocardial infarction (MI), stroke, and revascularization, were compared between the two groups up to 5 years.</P><P><B>Results</B></P><P>After PSM, two propensity-matched groups (265 pairs, n=530) were generated, and the baseline characteristics were balanced. Although the PCI group showed a higher incidence of target lesion and vessel revascularization on CTO, the incidence of MI tended to be lower [hazard ratio (HR): 0.339, 95% confidence interval (CI): 0.110 to 1.043, <I>p</I>=0.059] and the composite of total death or MI was lower (HR: 0.454, 95% CI: 0.224 to 0.919, <I>p</I>=0.028), compared with the MT group up to 5 years.</P><P><B>Conclusion</B></P><P>In this study, successful CTO PCI with DESs was associated with a higher risk of repeat PCI for the target vessel, but showed a reduced incidence of death or MI.</P>